CG Oncology, Inc. Common stock

CGONNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
72.55 USD
↘ 1.24 (1.68%)AT CLOSE (11:59 AM EDT)
72.55
↘ 0.01 (0.01%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
72.55
↘ 0.01 (0.01%)
🔴Market: CLOSED

CGON is currently priced at $72.59. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, CGON trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Sep 15, 2026.

Open?$74.13
High?$74.13
Low?$72.48
Prev. Close?$73.79
Volume?1.0M
Avg. Volume?710.9K
VWAP?$72.89
Rel. Volume?1.46x
Bid / Ask
Bid?$55.66 × 100
Ask?$92.45 × 100
Spread?$36.79
Midpoint?$74.06
Valuation & Ratios
Market Cap?6.5B
Shares Out?88.6M
Float?68.9M
Float %?78.1%
P/E Ratio?N/A
P/B Ratio?6.36
EPS?-$2.53
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
142
Market Cap
6.5B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.cgoncology.com
Listed
2024-01-25
Address
3000 PEGASUS PARK DRIVE
DALLAS, TX 75247
Phone: (949) 409-3700
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
21
Short Sent.?
39
Piotroski F-Score?0/9Weak
Altman Z-Score?69.09Safe
Confidence?52%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?16.55%High
Short Interest?11.4M
Days to Cover?16.1
Free Float68.9M
Avg Daily Volume709.1K
Settlement Date2026-08-31
Financial Health
Current Ratio?22.22Strong
Quick Ratio?22.20Strong
Cash Ratio?0.42Low
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
29
6.36FAIR▾
P/S?
Peers
100
S&P
3
1,050.22HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-26.1CHEAP▾
EV/Sales?
Peers
100
S&P
3
1,047.55HIGH▾
Returns & Efficiency
ROE?
S&P
7
-21.8%WEAK▾
ROA?
S&P
3
-20.7%WEAK▾
Cash Flow & Enterprise
FCF?$-179343000
Enterprise Value?$6.5B
Fundamentals ratios updated end of day
MarketsMoversWatchlist